The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

The company’s wide economic moat stems from its leadership position in the treatment of HIV, with products that are patented ...